EFM
SPRY icon

E Fund Management’s ARS Pharmaceuticals SPRY Stock Holding History

E Fund Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,787
Closed -$119K – 516
2026
Q1 		$119K Buy
+14,787
New +$142K ﹤0.01% 469

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

E Fund Management's SPRY Position: Q2 2026 in Review

E Fund Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 14,787 shares — an estimated $119K sold.

E Fund Management first reported a position in SPRY in Q1 2026 and held it in 1 quarter. The position peaked at $119K in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • E Fund Management reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • E Fund Management sold 14,787 ARS Pharmaceuticals shares in Q2 2026, an estimated $119K.
  • E Fund Management first reported a position in ARS Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • E Fund Management's ARS Pharmaceuticals position peaked at $119K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.